New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareRetatrutide vs MK-677 (Ibutamoren)

Retatrutide vs MK-677 (Ibutamoren)

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Retatrutide
Growth Hormone Peptides
MK-677 (Ibutamoren)
Summary
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that increases growth hormone and IGF-1 levels. Unlike injectable GHRPs, it can be taken orally and has a 24-hour half-life, making it convenient for sustained GH optimization.
Half-Life
~10–12 days
24 hours
Admin Route
SubQ
Oral
Research
Typical Dose
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
10–25 mg
Frequency
Once weekly
Once daily
Key Benefits
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
  • Increases lean muscle mass
  • Enhances bone density
  • Improves sleep quality and REM sleep
  • Accelerates recovery from training
  • Increases appetite
  • May improve skin elasticity and appearance
  • Supports fat loss while maintaining muscle
  • Oral administration — no injections required
  • 24-hour half-life allows once-daily dosing
Side Effects
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
  • Increased appetite (significant in some users)
  • Water retention and puffiness
  • Elevated blood glucose / insulin resistance (monitor in diabetics)
  • Lethargy initially
  • +2 more
Stacks With